COMMUNIQUÉS West-GlobeNewswire

DLH Wins $2 Million NIH Data Governance Pilot Task Order
05/10/2026
ATLANTA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital, engineering, and scientific solutions for health and defense missions, today [...]
Aprea Therapeutics to Present at October Conferences
05/10/2026
Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15) DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or [...]
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/10/2026
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Novo Nordisk A/S – Share repurchase programme
05/10/2026
Bagsværd, Denmark, 5 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
05/10/2026
LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. [...]
Freya Biosciences named as one of Fierce Biotech’s “Fierce 15” for 2026
05/10/2026
Recognition reflects Freya’s scientific progress and commitment to addressing significant unmet needs in women’s health COPENHAGEN, Denmark and BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Freya Biosciences (“Freya” or “ [...]
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
05/10/2026
The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers Selected as one of the Top 150 [...]
Kymanox Launches KymaBridge, an Intelligence Platform Connecting Pharma and Biotech Innovators with Drug Delivery Device Technologies
05/10/2026
New platform pairs Kymanox subject matter expert verification with supplier-confirmed data, helping sponsors identify the right drug delivery device technology faster, while giving device suppliers a direct, verified [...]
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
05/10/2026
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb [...]
Pistol and Paris Launches Vanquish Medical Providing Access and Serving Medical Cannabis Patients Across Canada
05/10/2026
Vanquish Medical Platform Provides a Portfolio of Pistol and Paris Products, Patient Support, Direct Billing and Speciality Services for Cannabis Patients AGASSIZ, B.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vanquish [...]
Curia investit 28 millions de dollars dans la fabrication d’API stériles
05/10/2026
ALBANY, N.Y., 05 oct. 2026 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), une organisation mondiale de premier plan spécialisée dans le développement et de fabrication sous contrat (CDMO), a annoncé aujourd’hui un [...]
Curia Invests $28 Million in Sterile API Manufacturing
05/10/2026
ALBANY, N.Y., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global contract, development and manufacturing organization (CDMO), today announced a strategic investment to expand its sterile API [...]
Beacon Therapeutics Named a “Fierce 15” Company by Fierce Biotech
05/10/2026
LONDON and CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics, a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular [...]
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
05/10/2026
OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen ® (rintatolimod), the [...]
Human Appeal Celebrates Top UK Volunteers at Third Annual Purple Legacy Awards
05/10/2026
MANCHESTER, United Kingdom, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Leading Humanitarian charity Human Appeal brought together 150 volunteers, staff and guests from London, the Midlands, the North and Scotland in Manchester [...]
Alpha Tau to Participate in October Investor Conferences
05/10/2026
JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced [...]
Transactions under Novonesis’ share buyback program
05/10/2026
Please read the announcement in PDF Attachment 2026_20_Share_buyback
Research Peptide Companies: Kylo Peptides Scores 96.7/100 in Plastic Surgery Key Review
05/10/2026
Sheridan, Wyoming, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides https://kylopeptides.com/ [], a U.S.-based supplier of research-use-only peptides, has received a score of 96.7/100 in a Plastic Surgery Key review of [...]
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
05/10/2026
– ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction – SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company [...]

Pages